公司資料
Intensity Therapeutics 股價、新聞與催化劑
- 股票代碼:
- INTS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
4.15 USD (+4.80%)
收盤價
最後更新: 2026年8月17日
11.6M USD
市值
股價為何變動
As of Aug 17, 2026, INTS closed up 4.80% at $4.15. No new same-company headline was identified in the current news window.
公司概覽
Intratumoral Cancer Therapy
Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens, and stimulate a broader immune response.
INT230-6
INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration throughout solid tumors. The candidate is being studied both before surgery and in advanced disease.
Soft-Tissue Sarcoma
The Phase 3 INVINCIBLE-3 study evaluates INT230-6 as second- or third-line monotherapy against standard of care in soft-tissue sarcoma, with overall survival as the primary outcome.
Triple-Negative Breast Cancer
The Phase 2 INVINCIBLE-4 study evaluates presurgical INT230-6 followed by standard immunochemotherapy against standard treatment alone in triple-negative breast cancer.
未來催化劑
- Resumption of patient enrollment at a limited number of U.S. sites in the Phase 3 INVINCIBLE-3 study by the third quarter of 2026.
- Completion of enrollment in the Phase 2 INVINCIBLE-4 study by the end of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。